Annexon (ANNX) Income from Continuing Operations (2019 - 2026)
Annexon (ANNX) posted quarterly Income from Continuing Operations of 78070000.0 for Q1 2026, down 9.25% year-over-year from 86030380.59 in Q1 2025, and down 15.75% quarter-over-quarter from 67445000.0 in Q4 2025.
Powered by 
Analysis
Annexon (ANNX) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Annexon's Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 78070000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 9.25% year-over-year to 78070000.0; the TTM figure through Mar 2026 stood at 268045000.0 (up 4.7% YoY), while the FY2025 annual figure was 441339000.0, down 31.76% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 78070000.0, down from 67445000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 39998000.0 in Q4 2022, with the low at 160890000.0 in Q4 2023.
- The 5-year median for Income from Continuing Operations is 71458000.0 (2025), against an average of 74213294.12.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations sank 302.25% in 2023, then jumped 64.82% in 2024.
- Annexon's Income from Continuing Operations stood at 39998000.0 in 2022, then tumbled by 302.25% to 160890000.0 in 2023, then surged by 64.82% to 56599000.0 in 2024, then fell by 19.16% to 67445000.0 in 2025, then retreated by 15.75% to 78070000.0 in 2026.
- Business Quant data shows ANNX's Income from Continuing Operations at 78070000.0 in Q1 2026, 67445000.0 in Q4 2025, and 62616000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Annexon | 976.88 Mn | 976.88 Mn | - | -57.23 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -57.23 Mn |
| Mar 31, 2026 | -46.11 Mn |
| Dec 31, 2025 | -50.21 Mn |
| Sep 30, 2025 | -57.00 Mn |
| Jun 30, 2025 | -51.73 Mn |
| Mar 31, 2025 | -57.51 Mn |
| Dec 31, 2024 | -52.54 Mn |
| Sep 30, 2024 | -39.28 Mn |
| Jun 30, 2024 | -33.57 Mn |
| Mar 31, 2024 | -28.61 Mn |
| Dec 31, 2023 | -29.95 Mn |
| Sep 30, 2023 | -34.73 Mn |
| Jun 30, 2023 | -37.64 Mn |
| Mar 31, 2023 | -41.08 Mn |
| Dec 31, 2022 | -36.67 Mn |
| Sep 30, 2022 | -36.03 Mn |
| Jun 30, 2022 | -37.47 Mn |
| Mar 31, 2022 | -35.62 Mn |
| Dec 31, 2021 | -37.56 Mn |
| Sep 30, 2021 | -35.60 Mn |